Announcements Trials

Conditions

Lymphoid 2Myeloid 2Other 2

Drug Classes

Bcr-Abl inhibitor 7IDH inhibitor 6DNA methyltransferase inhibitor 5FLT3 inhibitor 3KMT2A inhibitor 3Anthracycline 2Anti-CD33 ADC 2IL-3 fused immunotoxin 2STAMP inhibitor 2Alkylating agent 1Anti-IFNg 1BRAF inhibitor 1Bcl-2 inhibitor 1FGFR inhibitor 1Hedgehog pathway inhibitor 1JAK inhibitor 1PDGFR inhibitor 1Purine analog 1Pyrimidine analog 1TGF-beta inhibitor 1Telomerase inhibitor 1
Anthracycline × Myeloid × Clear all

2 Announcements

2017-09-01

FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML

Drugs
Mylotarg (gemtuzumab ozogamicin) · Anti-CD33 antibody-drug conjugate, daunorubicin · Anthracycline, cytarabine · Pyrimidine analog
Condition
Myeloid
2017-08-03

FDA approves liposome-encapsulated combination of daunorubicin-cytarabine for adults with some types of poor prognosis AML

Trial
301
Drug
VYXEOS (daunorubicin and cytarabine) · Anthracycline
Condition
Myeloid
Data powered by HemOnc (CC BY 4.0) Colophon âš¡